Ambee Pharmaceuticals PLC (DSE: AMBEEPHA)
Bangladesh
· Delayed Price · Currency is BDT 923.50
0.00 (0.00%)
At close: Sep 11, 2024
Ambee Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
| Revenue | 205.24 | 198.1 | 180.99 | 98.98 | 285.3 | 321.22 | Upgrade
|
| Revenue Growth (YoY) | 7.40% | 9.45% | 82.86% | -65.31% | -11.18% | -8.06% | Upgrade
|
| Cost of Revenue | 95.54 | 92.53 | 83.62 | 58.27 | 134.03 | 152.03 | Upgrade
|
| Gross Profit | 109.7 | 105.56 | 97.37 | 40.71 | 151.27 | 169.19 | Upgrade
|
| Selling, General & Admin | 96.52 | 92.39 | 82.51 | 47.99 | 139.77 | 149.1 | Upgrade
|
| Operating Expenses | 96.52 | 92.39 | 82.51 | 47.99 | 139.77 | 149.1 | Upgrade
|
| Operating Income | 13.18 | 13.17 | 14.86 | -7.28 | 11.5 | 20.09 | Upgrade
|
| Interest Expense | -0.86 | -2.49 | -4.62 | -5 | -6.56 | -6.98 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 0 | - | 0 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 12.32 | 10.68 | 10.23 | -12.28 | 4.94 | 13.11 | Upgrade
|
| Pretax Income | 12.32 | 10.68 | 10.23 | -12.28 | 4.94 | 13.11 | Upgrade
|
| Income Tax Expense | 1.64 | 1.59 | 2.18 | 0.73 | 1.3 | 9.74 | Upgrade
|
| Net Income | 10.68 | 9.09 | 8.06 | -13.01 | 3.64 | 3.37 | Upgrade
|
| Net Income to Common | 10.68 | 9.09 | 8.06 | -13.01 | 3.64 | 3.37 | Upgrade
|
| Net Income Growth | 12.36% | 12.79% | - | - | 8.01% | -59.26% | Upgrade
|
| Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | 2 | Upgrade
|
| EPS (Basic) | 4.45 | 3.79 | 3.36 | -5.42 | 1.52 | 1.40 | Upgrade
|
| EPS (Diluted) | 4.45 | 3.79 | 3.36 | -5.42 | 1.52 | 1.40 | Upgrade
|
| EPS Growth | 12.36% | 12.79% | - | - | 8.01% | -59.26% | Upgrade
|
| Free Cash Flow | -67.44 | -35.34 | -74.71 | -5.45 | -12.68 | 39.03 | Upgrade
|
| Free Cash Flow Per Share | -28.10 | -14.72 | -31.13 | -2.27 | -5.28 | 16.26 | Upgrade
|
| Dividend Per Share | 1.500 | 1.500 | 1.000 | - | 1.500 | 3.000 | Upgrade
|
| Dividend Growth | 50.00% | 50.00% | - | - | -50.00% | 0% | Upgrade
|
| Gross Margin | 53.45% | 53.29% | 53.80% | 41.13% | 53.02% | 52.67% | Upgrade
|
| Operating Margin | 6.42% | 6.65% | 8.21% | -7.36% | 4.03% | 6.25% | Upgrade
|
| Profit Margin | 5.20% | 4.59% | 4.45% | -13.14% | 1.27% | 1.05% | Upgrade
|
| Free Cash Flow Margin | -32.86% | -17.84% | -41.28% | -5.51% | -4.45% | 12.15% | Upgrade
|
| EBITDA | 21.4 | 20.16 | 19.64 | -1.67 | 18.12 | 27.94 | Upgrade
|
| EBITDA Margin | 10.43% | 10.18% | 10.85% | -1.69% | 6.35% | 8.70% | Upgrade
|
| D&A For EBITDA | 8.22 | 6.99 | 4.79 | 5.61 | 6.62 | 7.86 | Upgrade
|
| EBIT | 13.18 | 13.17 | 14.86 | -7.28 | 11.5 | 20.09 | Upgrade
|
| EBIT Margin | 6.42% | 6.65% | 8.21% | -7.36% | 4.03% | 6.25% | Upgrade
|
| Effective Tax Rate | 13.30% | 14.90% | 21.25% | - | 26.39% | 74.31% | Upgrade
|
| Advertising Expenses | - | 1.43 | 4.58 | 0.93 | 3.07 | 3.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.